WuXi AppTec expands site in California for pharmaceutical R&D services

WuXi AppTec's newly expanded facility will establish a centre of excellence in screening, discovery biology, pharmacolog, and small molecule process R&D, including Phase I GMP manufacturing.

The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries. WuXi will also add extensively from the local talent base, further contributing to regional economic growth.

"Having a leading global organisation such as WuXi significantly invest in San Diego highlights the value of international partnerships, the county's place on the Pacific Rim and our region's longstanding support of the life sciences community," said San Diego County Supervisor Ron Roberts.

"I especially applaud the company's vision that every drug can be made, and every disease can be treated."

"The San Diego life science community continues to thrive with the commitments and investments made by leading international powerhouses like WuXi AppTec," said Joe Panetta, President and CEO of Biocom.

"Their latest facility expansion in San Diego is a testament to the deep relationships they have built with the local biotech community. Biocom applauds the positive impact they've had on the region's economic growth and innovative healthcare products for our patients."

"This expansion will enable us to better serve our US and global customers, and contribute to the growth and success of the dynamic San Diego biotech ecosystem," said Dr Ge Li, Chairman and CEO of WuXi AppTec.

"Together with our ecosystem partners, we will continue to strengthen WuXi's capability and technology enabling platform to expedite the discovery and development of new medicines for patients worldwide, and for a future where every drug can be made and every disease can be treated."